EMBA_MYCSM
ID EMBA_MYCSM Reviewed; 1092 AA.
AC Q50394;
DT 23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT 01-JUL-1997, sequence version 2.
DT 25-MAY-2022, entry version 90.
DE RecName: Full=Probable arabinosyltransferase A;
DE EC=2.4.2.-;
GN Name=embA;
OS Mycolicibacterium smegmatis (Mycobacterium smegmatis).
OC Bacteria; Actinobacteria; Corynebacteriales; Mycobacteriaceae;
OC Mycolicibacterium.
OX NCBI_TaxID=1772;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC STRAIN=imm30;
RX PubMed=9142129; DOI=10.1038/nm0597-567;
RA Telenti A., Philipp W.J., Sreevatsan S., Bernasconi C., Stockbauer K.E.,
RA Wieles B., Musser J.M., Jacobs W.R. Jr.;
RT "The emb operon, a gene cluster of Mycobacterium tuberculosis involved in
RT resistance to ethambutol.";
RL Nat. Med. 3:567-570(1997).
CC -!- FUNCTION: Arabinosyl transferase responsible for the polymerization of
CC arabinose into the arabinan of arabinogalactan.
CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC protein {ECO:0000305}.
CC -!- MISCELLANEOUS: This is one of the targets of the anti-tuberculosis drug
CC ethambutol [(S,S')-2,2'-(ethylenediimino)di-1-butanol; EMB]. EMB is a
CC first-line drug used to treat tuberculosis. EMB inhibits the transfer
CC of arabinogalactan into the cell wall.
CC -!- SIMILARITY: Belongs to the emb family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; U46844; AAC45272.1; -; Genomic_DNA.
DR PIR; T45095; T45095.
DR AlphaFoldDB; Q50394; -.
DR SMR; Q50394; -.
DR CAZy; GT53; Glycosyltransferase Family 53.
DR GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR GO; GO:0052636; F:arabinosyltransferase activity; IEA:InterPro.
DR GO; GO:0071766; P:Actinobacterium-type cell wall biogenesis; IEA:InterPro.
DR GO; GO:0071555; P:cell wall organization; IEA:UniProtKB-KW.
DR GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR Gene3D; 2.60.120.610; -; 1.
DR Gene3D; 2.60.120.940; -; 1.
DR InterPro; IPR032731; Arabino_trans_C.
DR InterPro; IPR042486; Arabino_trans_C_2.
DR InterPro; IPR007680; Arabino_trans_central.
DR InterPro; IPR040920; Arabino_trans_N.
DR InterPro; IPR027451; EmbABC_dom1.
DR Pfam; PF14896; Arabino_trans_C; 1.
DR Pfam; PF17689; Arabino_trans_N; 1.
DR Pfam; PF04602; Arabinose_trans; 1.
PE 3: Inferred from homology;
KW Antibiotic resistance; Cell membrane; Cell wall biogenesis/degradation;
KW Glycosyltransferase; Membrane; Transferase; Transmembrane;
KW Transmembrane helix.
FT CHAIN 1..1092
FT /note="Probable arabinosyltransferase A"
FT /id="PRO_0000220563"
FT TRANSMEM 21..43
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 214..233
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 249..271
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 324..346
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 353..372
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 382..399
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 404..426
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 517..534
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 541..563
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 568..590
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 602..624
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 639..661
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TRANSMEM 682..704
FT /note="Helical"
FT /evidence="ECO:0000255"
FT REGION 772..798
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ SEQUENCE 1092 AA; 117055 MW; 62399B9F9EB24F3A CRC64;
MPGDEQRERT ADDAVTEPSR IARLIAVVAG IAGVLLCGLV PLLPVEETTA TVLWPQGVGA
DGNVTELTAP LVAGAPRALD VTIPCRAVAE LPADGGVVFS TNPAGGIEAG RNGMFIRANA
DVVYVAFRDT VAAVAPREAV DSGACSEIHV WADVSAVGAD FAGIPDASGT LPVDKRPQVS
GVFTDLKVPA QPGLAARIDI DTRFITSPTL LKTAVMVLGL ACVIGSIVAL ALLDRGWRRR
PARTRGRAGL WTWITDTGVI GGLLIWHIVG APTSDDGYNM TIARVASEAG YTTNYYRYFG
ASEAPFDWYQ SVLSHLASIS TAGVWMRLPA TAAAIATWLI ISRCVLPRIG RRVAANRVAM
LTAGATFLAA WLPFNNGLRP EPLIAFAVIT VWMLVENSIG TRRLWPAAVA IVIAMFSVTL
APQGLIALAP LLVGARAIGR VVTARRAAPG SWRPCPLAAS VAVVFVIIFR DQTLATVAES
VRIKYVVGPT IPWYQEFLRY YFLTVEDSVD GSLTRRFAVL VLLLCLFGLI MVLLRRGRVP
GAVSGPLWRL CGSTAIGLLL LILTPTKWAI QFGAFAGLAG ALGGVTAFAF ARVGLHSRRN
LALYVTALLF ILAWATSGLN GWFYVGNYGV PWFDKQPVIA HYPVTTIFLV LAIVGGLLAG
WLHFRMDYAG HTEVADTGRN RALASTPLLI VATIMVVLEL GSMVKATVGR YPVYTVGSAN
IAALRSAGDS CAMADAVLVE ADPNEGMLQP VPGQRFGDYG PLGGEDPVGF TPSGVSEHLE
PEPVGTNPGT PNSEGPVDKP NIGIAYAGDT GGGYAPEGVN GSRVFLPFGL DPSRTPVMGS
YGENKLAAKA TSAWYQLPPR TPDRPLVTVA AAGAIWYYEE DGSFNYGQSL KLQWGVHRPD
GTYQALSEVQ PIDIFQQKAW RNLRFPLAWA PPEANVARIV ADDPNLSEDQ WCAFTPPRVP
VLQTAQQFLG SQTPVLMDIA TAANFPCQRP FAERLGVAEL PEYRIIPNFK QMVVSSNQWQ
SAADGGPFLF IQALLRTEAI PTYLRDDWYR DWGSIERYIR VVPQEQAPTA AIEEGSTRVF
GWSRGGPIRA LP